Urology
Volume 72, Issue 6 , Pages 1229-1233 , December 2008

Gene Expression of Survivin and Its Spliced Isoforms Associated With Proliferation and Aggressive Phenotypes of Prostate Cancer

  • Hidekazu Koike

      Affiliations

    • Department of Urology, Gunma University Graduate School of Medicine, Maeabshi City, Gunma, Japan
    • Corresponding Author InformationReprint requests: Hidekazu Koike, M.D., Department of Urology, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi-City, Gunma 371-8511 Japan
    • ,
  • Yoshitaka Sekine

      Affiliations

    • Department of Urology, Gunma University Graduate School of Medicine, Maeabshi City, Gunma, Japan
    • ,
  • Makoto Kamiya

      Affiliations

    • Department of Human Pathology, Gunma University Graduate School of Medicine, Maeabshi-City, Gunma, Japan
    • ,
  • Haruki Nakazato

      Affiliations

    • Department of Urology, Gunma University Graduate School of Medicine, Maeabshi City, Gunma, Japan
    • ,
  • Kazuhiro Suzuki

      Affiliations

    • Department of Urology, Gunma University Graduate School of Medicine, Maeabshi City, Gunma, Japan

Received 8 May 2007 ,Accepted 14 December 2007.

References 

  1. Altieri DC, Marchisio PC. Survivin apoptosis: an interloper between cell death and cell proliferation in cancer. Lab Invest. 1999;79:1327–1333
  2. Zaffaroni N, Pennati M, Daidone MG. Survivin as a target for new anticancer interventions. J Cell Mol Med. 2005;9:360–372
  3. Takai N, Miyazaki T, Nishida M, et al. Survivin expression correlates with clinical stage, histological grade, invasive behavior and survival rate in endometrial carcinoma. Cancer Lett. 2002;184:105–116
  4. Dong Y, Sui L, Watanabe Y, et al. Survivin expression in laryngeal squamous cell carcinomas and its prognostic implications. Anticancer Res. 2002;22:2377–2383
  5. Islam A, Kageyama H, Takada N, et al. High expression of survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene. 2000;19:617–623
  6. Kato J, Kuwabara Y, Mitani M, et al. Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy. Int J Cancer. 2001;95:92–95
  7. Mahotka C, Wenzel M, Springer E, et al. Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res. 1999;59:6097–6102
  8. Caldas H, Jiang Y, Holloway MP, et al. Survivin splice variants regulate the balance between proliferation and cell death. Oncogene. 2005;24:1994–2007
  9. Caldas H, Honsey LE, Altura RA. Survivin 2alpha: a novel survivin splice variant expressed in human malignancies. Mol Cancer. 2005;4:1–9
  10. Mahotka C, Krieq T, Krieq A, et al. Distinct in vivo expression patterns of survivin splice variants in renal cell carcinomas. Int J Cancer. 2002;100:30–36
  11. Krajewska M, Krajewski S, Banares S, et al. Elevated expression of inhibitor of apoptosis proteins in prostate cancer. Clin Cancer Res. 2003;9:4914–4925
  12. Kaur P, Kallakury BS, Sheehan CE, et al. Survivin and Bcl-2 expression in prostatic adenocarcinomas. Arch Pathol Lab Med. 2004;128:39–43
  13. Olie RA, Simoes-Wust AP, Baumann B, et al. A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res. 2000;60:2805–2809
  14. Pennati M, Binda M, Colella G, et al. Ribozyme-mediated inhibition of survivin expression increases spontaneous and drug-induced apoptosis and decreases the tumorigenic potential of human prostate cancer cells. Oncogene. 2004;23:386–394
  15. Hayashi N, Asano K, Suzuki H, et al. Adenoviral infection of survivin antisense sensitizes prostate cancer to etoposide in vivo. Prostate. 2005;65:10–19
  16. Zhang M, Mukherjee N, Bermudez RS, et al. Adenovirus-mediated inhibition of survivin expression sensitize human prostate cancer cells to paclitaxel in vitro and in vivo. Prostate. 2005;64:293–302
  17. Pennati M, Binda M, Colella G, et al. Radiosensitization of human melanoma cells by ribozyme-mediated inhibition of survivin expression. J Invest Dermatol. 2003;120:648–654
  18. Suzuki K, Koike H, Matsui H, et al. Genistein, a soy isofravone, induces glutathione peroxidase in the human prostate cancer cell lines LNCaP and PC-3. Int J Cancer. 2002;99:846–852
  19. Kishi H, Igawa M, Kikuno N, et al. Expression of the survivin gene in prostate cancer: correlation with clinicopathological characteristics, proliferative activity and apoptosis. J Urol. 2004;171:1855–1860
  20. Noton EA, Colnaghi R, Tate S, et al. Molecular analysis of survivin isoforms: evidence that alternatively spliced variants do not play a role in mitosis. J Biol Chem. 2006;281:1286–1295
  21. Span PN, Tjan-Heijnen VC, Heuvel JJ, et al. Do the survivin splice variants modulate or add to the prognostic value of total survivin in breast cancer?. Clin Chem. 2006;52:1693–1700
  22. Futakuchi H, Ueda M, Kanda K, et al. Transcriptional expression of surviving and its splice variants in cervical carcinomas. Int J Gynecol Cancer. 2007;17:1092–1098
  23. Taubert H, Kappler M, Bache M, et al. Elevated expression of survivin-splice variants predicts a poor outcome for soft-tissue sarcomas patients. Oncogene. 2005;24:5258–5261
  24. Chen J, Wu W, Tahir SK, et al. Down-regulation of survivin by antisense oligonucleotides increases apoptosis, inhibits cytokinesis and anchorage-independent growth. Neoplasia. 2000;2:235–241
  25. Yamamoto T, Manome Y, Nakamura M, et al. Downregulation of survivin expression by induction of the effector cell protease receptor-1 reduces tumor growth potential and results in an increased sensitivity to anticancer agents in human colon cancer. Eur J Cancer. 2002;38:2316–2324
  26. Choi KS, Lee TH, Jung MH. Ribozyme-mediated cleavage of the human survivin mRNA and inhibition of antiapoptotic function of survivin in MCF-7 cells. Cancer Gene Ther. 2003;10:87–95
  27. Mesri M, Wall NR, Li J, et al. Cancer gene therapy using a survivin mutant adenovirus. J Clin Invest. 2001;108:981–990
  28. Elbashir S, Lendeckel W, Tuschl T. RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev. 2001;15:188–200
  29. Izquierdo M. Short interfering RNAs as a tool for cancer gene therapy. Cancer Gene Ther. 2005;12:217–227
  30. Shariat SF, Ashfaq R, Roehrborn CG, et al. Expression of survivin and apoptotic biomarkers in benign prostatic hyperplasia. J Urol. 2005;174:2046–2050

 This study was partly supported by a Grant-in-Aid for Young Scientists (Project No. 18791113) from the Ministry of Education, Science, Sports and Culture.

PII: S0090-4295(07)02655-6

doi: 10.1016/j.urology.2007.12.064

Urology
Volume 72, Issue 6 , Pages 1229-1233 , December 2008

Article Tools

* Image Usage & Resolution